Androne 250 mg — Caspian

Androne 250 mg Caspian

Caspian

€80,00

In Stock (100 available)

Androne 250 mg Caspian (250 mg) — Caspian presents this pharmaceutical-grade compound — this pharmaceutical-grade injectable compound is formulated for optimal bi…

100 in stock

5+ −10%

10+ −15% Best price

Third-Party Lab Report HPLC verified

CoA available on request — email support@vitalquests.org with the batch code from your vial.

HPLC TestedBatch report available

No Labels on BoxPlain brown parcel

Pay the CourierCash on delivery only

Ships TodayOrder before 14:00

€85+ = free shipping

EU warehouse — no customs, no delays

Tracked via DHL / DPD / InPost

Description

Androne 250 mg Caspian — Testosterone blend — multi-ester mix for compressed kick-in and sustained plasma coverage from a single injection. Each unit dosed at 250 mg.

Key Benefits

Multi-ester blend — acute kick + long-tail coverage from one injection
Classic Sustanon / Omnadren formulation (prop + phenyl + iso + deca)
Twice-weekly pinning schedule covers all four ester kinetics
Behaves functionally like testosterone enanthate for cycle planning
Popular pharma-grade option where single-ester vials aren’t available
Each unit dosed at 250 mg — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: 250–750 mg/week; TRT 100–200 mg/week. Split across at least 2 injections (Mon/Thu). Shorter esters in the blend push injection frequency — once-weekly produces noticeable troughs.

How It Works

Mixture of 4 testosterone esters: propionate (fast), phenylpropionate (short-medium), isocaproate (medium), decanoate (long). At the AR the active hormone is identical across esters; the blend provides staggered release kinetics for smoother coverage.

Pharmacokinetics

Composite release: propionate peaks in ~24 h, phenylpropionate ~2 days, isocaproate ~3–4 days, decanoate ~7–10 days. Net effect similar to enanthate but with a gentler peak. Steady-state in 4 weeks. PCT starts 2 weeks after last injection.

Potential Side Effects

Standard testosterone side-effect profile. Propionate fraction can cause PIP; some users prefer pure enanthate for tolerability. AI dose by bloodwork — hematocrit and E2 at week 6.

Cycle & Stacking Guide

Cycle base identical to enanthate: 12–16 weeks for mass/recomp, paired with secondary compounds per goal. Twice-weekly pinning mandatory. PCT (Clomid + Nolva) 14 days after last pin.

Manufacturer Notes

Caspian is a regional producer with standard-concentration injectable AAS. Batch codes on every label.

Storage & Handling

Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Androne 250 mg Caspian”

2D structural representation · PubChem CID 9416 ↗

Chemical Identity
#	CAS Registry Number	`315-37-7`
Σ	IUPAC Name	[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] heptanoate
F	Molecular Formula	C₂₆H₄₀O₃
M	Molecular Weight	400.60 g/mol
⌬	SMILES	`CCCCCCC(=O)O[C@@H]1CC[C@@H]2[C@H]3CCC4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C`
⊞	InChIKey	`SEM27OEN34OSRR-ZHDKGOKVSA-N`
△	Melting Point	34-39 °C
≋	Solubility	Practically insoluble in water; soluble in vegetable oils
t½	Biological Half-life	4.5 days (IM)
⊕	PubChem CID	9416 ↗

Pharmacological Profile
Anabolic Rating	100
Androgenic Rating	100
Aromatization	Moderate
Hepatotoxicity	None
Detection Time	3 months

Clinical Notes

Mechanism & protocol-relevant pharmacology, reviewed by editorial pharmacology lead

The 7-carbon heptanoate ester of endogenous testosterone. IM depot kinetics: serum peak at 24–48 h post-injection, steady-state reached after 4–5 half-lives (weeks 3–4). Once-weekly administration produces ~200 ng/dL peak-to-trough variance at 200 mg/week; trough suppression on EOD or twice-weekly splits. Aromatises via CYP19A1 at physiological rates — 0.2–0.3% substrate conversion to estradiol. Target serum E2 on protocol: 25–40 pg/mL (sensitive LC-MS/MS). Aggressive AI dosing that suppresses E2 below 20 pg/mL produces the documented side profile of arthralgia, libido loss, lipid degradation, and cognitive fog — iatrogenic hypoestrogenaemia is a bigger problem than measured hyperoestrogenaemia in most protocols. HPTA shutdown is total within 14 days and predictable; recovery timeline post-cessation is 3–6 months with SERM-based PCT, longer without. Haematocrit drift is the most consistent long-run biomarker — 3–5 percentage points per cycle, additive across cycles without donation.

Known trade names: Delatestryl, Testoviron Depot, Cidoteston

External references

Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.

Androne 250 mg Caspian